NTSR1

Fusion Pharmaceuticals to Present at the B. Riley Securities 2022 Virtual Oncology Conference

Retrieved on: 
Friday, January 21, 2022
NTSR1, Webcast, Patient, Tat, Conference, Neurotensin receptor, Isotope, Pembrolizumab, Merck, IND, GMP, View, AstraZeneca, Good manufacturing practice, FGFR3, Company, Multimedia, Neoplasm, McMaster University, DNA, Online shopping, Pharmaceutical industry, Fusion

HAMILTON, ONandBOSTON, Jan. 21, 2022 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will participate in a fireside chat at the B. Riley Securities 2022 Virtual Oncology Conference on Thursday, January 27, 2022 at 2:00 p.m.

Key Points: 
  • HAMILTON, ONandBOSTON, Jan. 21, 2022 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will participate in a fireside chat at the B. Riley Securities 2022 Virtual Oncology Conference on Thursday, January 27, 2022 at 2:00 p.m.
  • A replay of the webcast will be archived on the Company's website for 90 days following the presentation.
  • Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines.
  • Fusion has also entered into a collaboration with Merck to evaluate FPI-1434 in combination with Merck's KEYTRUDA (pembrolizumab) in patients with solid tumors expressing IGF-1R.

Fusion Pharmaceuticals To Present At The 2021 Jefferies London Healthcare Conference

Retrieved on: 
Thursday, November 11, 2021
GMP, View, McMaster University, DNA, Merck, Good manufacturing practice, Neurotensin receptor, Pembrolizumab, Multimedia, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., GMT, Isotope, Neoplasm, Conference, Company, Tat, Webcast, FGFR3, Patient, AstraZeneca, IND, NTSR1, Pharmaceutical industry

HAMILTON, OntarioandBOSTON, Nov. 11, 2021 /PRNewswire/ --Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will present at the 2021 Jefferies London Healthcare Conference.

Key Points: 
  • HAMILTON, OntarioandBOSTON, Nov. 11, 2021 /PRNewswire/ --Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will present at the 2021 Jefferies London Healthcare Conference.
  • A recording of the presentation will be made available for on-demand viewing on Thursday, November 18, 2021 at 8:00am GMT.
  • A replay of the webcast will be archived on the Company's website for 90 days following the presentation.
  • Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines.

Fusion Pharmaceuticals Appoints Industry Veteran Christopher Leamon, Ph.D., as Chief Scientific Officer

Retrieved on: 
Tuesday, November 2, 2021
Science, Ionis Pharmaceuticals, Research, Chemistry, Actinium, Biochemistry, Industry, Neoplasm, Drug development, Merck, DNA, Financial compensation, FGFR3, Partnership, Patient, TAT, Radiopharmaceutical, View, Drug discovery, Ministry of Education (Malaysia), Baldwin Wallace University, GMP, PSMA, Neurotensin receptor, Company, McMaster University, Investment, Isotope, Tat, Multimedia, Board, IND, Program, NTSR1, Acquisition, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Advanced Accelerator Applications, Good manufacturing practice, AstraZeneca, Therapy, Employment, GlaxoSmithKline, Pembrolizumab, Purdue University, Pharmaceutical industry

HAMILTON, Ontario and BOSTON, Nov. 2, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the appointment of Christopher Leamon, Ph.D., as chief scientific officer. Dr. Leamon brings to Fusion more than 25 years of experience developing precision medicines and radiopharmaceuticals.

Key Points: 
  • HAMILTON, OntarioandBOSTON, Nov. 2, 2021 /PRNewswire/ --Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the appointment of Christopher Leamon, Ph.D., as chief scientific officer.
  • Dr. Leamon brings to Fusion more than 25 years of experience developing precision medicines and radiopharmaceuticals.
  • Prior to Novartis, he was vice president, discovery research at Advanced Accelerator Applications, a subsidiary acquired by Novartis in 2018.
  • Eric Burak, Ph.D., Fusion's chief scientific officer since the company's inception, has been appointed chief technology officer.

Fusion Pharmaceuticals Announces Presentation of Preclinical Data Supporting its FPI-1966 and FPI-2059 Targeted Alpha Therapies

Retrieved on: 
Wednesday, October 20, 2021
Science, Head, Actinium-225, Bladder cancer, Association, Cancer, Neoplasm, DNA, Merck, Colorectal cancer, Radionuclide, FGFR3, Patient, TAT, Private Securities Litigation Reform Act, Radiopharmaceutical, View, Hereditary diffuse gastric cancer, GMP, SEC, Nuclear medicine, Neurotensin receptor, Company, Risk, McMaster University, Tat, Isotope, Multimedia, IND, Fusion, NTSR1, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Good manufacturing practice, AstraZeneca, Population, Pembrolizumab, Neck, Pharmaceutical industry, Vaccine, Medical imaging

HAMILTON, Ontario and BOSTON, Oct. 20, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the presentation of preclinical data that provide further support of its FPI-1966 and FPI-2059 targeted alpha therapies (TATs) at the 34th Annual European Association of Nuclear Medicine Congress. These data reinforce the clinical dosing regimen of FPI-1966 and highlight the potential of FPI-2059 as an actinium-225 labelled precision medicine targeting NTSR1.

Key Points: 
  • These data reinforce the clinical dosing regimen of FPI-1966 and highlight the potential of FPI-2059 as an actinium-225 labelled precision medicine targeting NTSR1.
  • Data from preclinical studies of FPI-1966, a TAT designed to target and deliver actinium-225 to cancer cells expressing FGFR3, were presented in an oral presentation titled, "FGFR3 Targeted Alpha Therapeutic [225Ac]-FPI-1966 induces regression in preclinical bladder xenograft model".
  • Further, the data showed therapeutic efficacy of FPI-1966 at both single and multiple doses in a preclinical bladder cancer xenograft model.
  • Data from preclinical studies of FPI-2059, a TAT designed to target and deliver actinium-225 to cancer cells expressing neurotensin receptor 1 (NTSR1), were presented in an oral presentation titled "NTSR1 Targeted Alpha Therapeutic [225Ac]-FPI-2059 induces regression in preclinical colorectal xenograft model".

Fusion Pharmaceuticals Appoints Mohit Rawat as President and Chief Business Officer

Retrieved on: 
Tuesday, September 28, 2021
Bachelor of Technology, GMP, Neoplasm, Financial compensation, MIT, Neurotensin receptor, Novartis, IIT, Employment, Indian Institutes of Technology, NTSR1, CML, FDA, FGFR3, McMaster University, Patient, Multimedia, Institute, Chemical engineering, DNA, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Board, Metabolism, Good manufacturing practice, Marketing, NASH, Merck, Company, Growth, Tat, Isotope, Harvard Business School, McKinsey & Company, AstraZeneca, IND, View, Radiopharmaceutical, Research, Drug development, M. Tech Clinical engineering, Pembrolizumab, Pharmaceutical industry, Management

HAMILTON, ONandBOSTON, Sept. 28, 2021 /PRNewswire/ --Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the appointment of Mohit Rawat as President and Chief Business Officer.

Key Points: 
  • HAMILTON, ONandBOSTON, Sept. 28, 2021 /PRNewswire/ --Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the appointment of Mohit Rawat as President and Chief Business Officer.
  • Mr. Rawat brings to Fusion more than 15 years of experience in the biopharmaceutical industry, with expertise in corporate strategy, business development and commercial execution, including product development, launch planning and commercialization.
  • Before joining Novartis, Mr. Rawat was asset team lead, senior director, immunology and neuroscience at AbbVie Pharmaceuticals.
  • Earlier in his career, Mr. Rawat held several positions of increasing responsibility within Novartis Pharmaceuticals, across marketing and sales, drug development and portfolio planning.

Fusion Pharmaceuticals To Present At The 2021 Cantor Fitzgerald Virtual Global Healthcare Conference

Retrieved on: 
Thursday, September 23, 2021
GMP, Neoplasm, Neurotensin receptor, Conference, FGFR3, NTSR1, McMaster University, Webcast, Patient, Multimedia, DNA, Good manufacturing practice, Merck, Company, Tat, Isotope, AstraZeneca, IND, View, Pembrolizumab, Pharmaceutical industry

HAMILTON, ONandBOSTON, Sept. 23, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference onWednesday, September 29, 2021at2:40pm ET.

Key Points: 
  • HAMILTON, ONandBOSTON, Sept. 23, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference onWednesday, September 29, 2021at2:40pm ET.
  • A replay of the webcast will be archived on the Company's website for 90 days following the presentation.
  • Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines.
  • Fusion has also entered into a collaboration with Merck to evaluate FPI-1434 in combination with Merck's KEYTRUDA (pembrolizumab) in patients with solid tumors expressing IGF-1R.

Fusion Pharmaceuticals Appoints Eric S. Hoffman, Ph.D. as Senior Vice President, Business Development

Retrieved on: 
Tuesday, September 21, 2021
Biogen, GMP, Biotechnology, Neoplasm, Developmental biology, Financial compensation, Neurotensin receptor, Employment, King, Doctor of Philosophy, FGFR3, NTSR1, McMaster University, Patient, Multimedia, DNA, Trinity University, Board, Good manufacturing practice, Biology, Acquisition, Merck, Company, Antibody, Tat, Isotope, Humanitarian use licenses, AstraZeneca, IND, View, Radiopharmaceutical, Wall Street, Pembrolizumab, Yale University, Department, Pharmaceutical industry, Management

HAMILTON, ONandBOSTON, Sept. 21, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the appointment of Eric S. Hoffman, Ph.D. as senior vice president, business development.

Key Points: 
  • HAMILTON, ONandBOSTON, Sept. 21, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the appointment of Eric S. Hoffman, Ph.D. as senior vice president, business development.
  • To that end, Eric brings to our team deep business development and corporate strategy experience, combined with a scientific and finance background."
  • Prior to Vicarius, he was chief business officer of Genocea Biosciences where he led business development, alliance management and commercial operations.
  • Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines.

Fusion Pharmaceuticals to Participate in Upcoming Investor Conferences

Retrieved on: 
Thursday, September 2, 2021
Patient, Neoplasm, Morgan, NTSR1, McMaster University, Merck, DNA, AstraZeneca, Conference, GMP, Isotope, Pembrolizumab, View, Company, Multimedia, Good manufacturing practice, Tat, Neurotensin receptor, Morgan Stanley, IND, FGFR3, Pharmaceutical industry, Management, Online shopping

HAMILTON, ONandBOSTON, Sept. 2, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will participate in two upcoming virtual investor conferences.

Key Points: 
  • HAMILTON, ONandBOSTON, Sept. 2, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will participate in two upcoming virtual investor conferences.
  • The Morgan Stanley 19th Annual Global Healthcare Conference The fireside chat will take place on Thursday, September 9, 2021 at 11:00am ET.
  • Presenting on behalf of Fusion will be Chief Executive Officer John Valliant, Ph.D., and Chief Financial Officer John Crowley.
  • Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines.